SEE 1ST Review
Clinical Science Specialist – Endocrinology
Injectable device specialty sales for rare disease states: Acromegaly & Short Stature in Chicago area, IN, and Wisconsin.
FY11 - 113% product share growth
FY11- Exceeded goal Attainment on both injections: Somaline Depot %age Attainment 105.49% & Increlex %age Attainment 112.50%. Finished #1 in the region. Top 5 Nationally. Territory-113% vs. Nation-97%
FY12 - Significant product growth on two injections: 90.29% Somatuline Depot, 114% Increlex
FY13 - Tracking 93% goal attainment.
FY14- T2 Results 123% goal attainment on injection Somatuline Depot; 2nd Ranking Nation
Marketplace knowledge respected by higher levels of organization
Target internal medicine & endocrinologists
Identified, developed, & executed KAP thought leaders to reflect 65-35 weighting in the territory. Identify & utilized cross functional personal resources & tools (speaker programs) within each KAP to specify end result targeted, ie Sales growth, and patient retention
Identified, Develop & pursued innovative new business opportunities exceeded goal on both products & finished #1 in the Region. Somatuline Depot 105.49% & Increlex 112.50%. Territory Ranked Top 5 Nationally.